Canaccord Genuity Reiterates a 'Buy' on Amarin (AMRN); Focus on IP Continues, New Office Action
Tweet
Share
E-mailGet Alerts AMRN Hot Sheet
Price: $13.72 --0%
Rating Summary:
6 Buy, 12 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 10 | New: 41
Rating Summary:
6 Buy, 12 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 10 | New: 41
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on Amarin Corporation (NASDAQ: AMRN) price target of $25.00.
Analyst, Ritu Baral, said, "Reiterate rating and price target on commercial, partnership potential of AMR101. AMR101 is AMRN’s 96% EPA omega-3 drug for high triglycerides. We think AMR101 will be approved for hypertriglyceridemia on its July 26 PDUFA data and expect IP and business development progress in H2/12."
For an analyst ratings summary and ratings history on Amarin Corporation click here. For more ratings news on Amarin Corporation click here.
Shares of Amarin Corporation closed at $7.75 yesterday.
Analyst, Ritu Baral, said, "Reiterate rating and price target on commercial, partnership potential of AMR101. AMR101 is AMRN’s 96% EPA omega-3 drug for high triglycerides. We think AMR101 will be approved for hypertriglyceridemia on its July 26 PDUFA data and expect IP and business development progress in H2/12."
For an analyst ratings summary and ratings history on Amarin Corporation click here. For more ratings news on Amarin Corporation click here.
Shares of Amarin Corporation closed at $7.75 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Assumes Tarsus Pharmaceuticals (TARS) at Buy
- Arcturus Therapeutics (ARCT) PT Lowered to $20 at BTIG
- Goldman Sachs Assumes Insmed (INSM) at Buy
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS ViewSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
